{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:19:56Z","timestamp":1771654796094,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,30]]},"DOI":"10.7759\/cureus.9481","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T16:48:00Z","timestamp":1596127680000},"source":"Crossref","is-referenced-by-count":6,"title":["Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Alexander R","family":"Chartier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor J","family":"Hillert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpreet","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinky","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3536(98)80050-4","article-title":"Acquired factor V inhibitors","volume":"11","author":"Knobl P","year":"1998","unstructured":"Knobl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol. 1998, 11:305-318. 10.1016\/s0950-3536(98)80050-4","journal-title":"Baillieres Clin Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.01.005","article-title":"A review of three stand-alone topical thrombins for surgical hemostasis","volume":"31","author":"Cheng CM","year":"2009","unstructured":"Cheng CM, Meyer-Massetti C, Kayser SR. A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther. 2009, 31:32-41. 10.1016\/j.clinthera.2009.01.005","journal-title":"Clin Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-010-0529-6","article-title":"Acquired factor V inhibitors: a systematic review","volume":"31","author":"Franchini M","year":"2011","unstructured":"Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis. 2011, 31:449-457. 10.1007\/s11239-010-0529-6","journal-title":"J Thromb Thrombolysis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-11-0767","article-title":"Acquired factor V inhibitor: a problem-based systematic review","volume":"101","author":"Ang A","year":"2009","unstructured":"Ang A, Kuperan P, Ng C, Ng H. Acquired factor V inhibitor: a problem-based systematic review. Thromb Haemost. 2009, 101:852-859. 10.1160\/TH08-11-0767","journal-title":"Thromb Haemost"},{"key":"ref5","article-title":"Acquired factor V inhibitors: a review of literature","volume":"4","author":"Boland F","year":"2017","unstructured":"Boland F, Shreenivas A. Acquired factor V inhibitors: a review of literature. Ann Hematol Oncol. 2017, 4:1168.","journal-title":"Ann Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.2017.0158","article-title":"Successful outcome of severe intra-cerebral bleeding associated with acquired factor V inhibition: utilization of multiple therapeutic agents","volume":"35","author":"Andreadis P","year":"2018","unstructured":"Andreadis P, Kafantari K, Agapidou A, Vakalopoulou S, Vlachaki E. Successful outcome of severe intra-cerebral bleeding associated with acquired factor V inhibition: utilization of multiple therapeutic agents. Balk Med J. 2018, 35:112-115. 10.4274\/balkanmedj.2017.0158","journal-title":"Balk Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9150-17","article-title":"High titer of acquired factor V Inhibitor presenting with a pseudo-deficiency of multiple coagulation factors","volume":"57","author":"Nakata K","year":"2018","unstructured":"Nakata K, Ueda S, Matsunaga H, et al.. High titer of acquired factor V Inhibitor presenting with a pseudo-deficiency of multiple coagulation factors. Intern Med J. 2018, 57:393-397. 10.2169\/internalmedicine.9150-17","journal-title":"Intern Med J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.01.045","article-title":"Acquired factor V deficiency in a patient with myeloma and amyloidosis","volume":"164","author":"Quek J","year":"2018","unstructured":"Quek J, Wong W, Tan C, Tha MH, Nagarajan C, Lee LH, Ng HJ. Acquired factor V deficiency in a patient with myeloma and amyloidosis. Thrombosis Research. Thromb Res. 2018, 164:1-3. 10.1016\/j.thromres.2018.01.045","journal-title":"Thrombosis Research. Thromb Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3348-z","article-title":"A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment","volume":"97","author":"Fujita Y","year":"2018","unstructured":"Fujita Y, Nakazato T, Ito C, Masuda K, Osada Y, Aisa Y, Mori T. A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment. Ann Hematol. 2018, 97:2009-2010. 10.1007\/s00277-018-3348-z","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2561-9","article-title":"A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis","volume":"109","author":"Ogawa H","year":"2019","unstructured":"Ogawa H, Souri M, Kanouchi K, et al.. A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis. International J Hematol. 2019, 109:214-220. 10.1007\/s12185-018-2561-9","journal-title":"International J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03638-6","article-title":"Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report","volume":"98","author":"Taniwaki M","year":"2019","unstructured":"Taniwaki M, Katsutani S, Yamasaki M, et al.. Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report. Ann Hematol. 2019, 98:1989-1990. 10.1007\/s00277-019-03638-6","journal-title":"Ann Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000496080","article-title":"Acquired factor V inhibitor with symptoms and titer of inhibitor differences: report of two cases","volume":"141","author":"Li F","year":"2019","unstructured":"Li F, Shu K, Liu J, et al.. Acquired factor V inhibitor with symptoms and titer of inhibitor differences: report of two cases. Acta Haematol. 2019, 141:148-150. 10.1159\/000496080","journal-title":"Acta Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.04.080","article-title":"Case report perioperative management of a patient with severe factor V deficiency presenting with chronic subdural hematoma: a clinical report","volume":"127","author":"Meidert AS","year":"2019","unstructured":"Meidert AS, Kinzinger J, Mohnle P, et al.. Case report perioperative management of a patient with severe factor V deficiency presenting with chronic subdural hematoma: a clinical report. World Neurosurg. 2019, 127:409-413. 10.1016\/j.wneu.2019.04.080","journal-title":"World Neurosurg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000502406","article-title":"Acquired factor V inhibitor with hemorrhagic symptoms after prasugrel hydrochloride treatment [Online ahead of print]","author":"Sakatoku K","year":"2019","unstructured":"Sakatoku K, Takakuwa T, Miura A, Araki T, Fujitani Y, Yamamura R. Acquired factor V inhibitor with hemorrhagic symptoms after prasugrel hydrochloride treatment [Online ahead of print]. Acta Haematol. 2019, 10.1159\/000502406","journal-title":"Acta Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000502730","article-title":"Successful management of acquired factor v inhibitor by monitoring factor V activity, antigen, and inhibitor values during immunosuppressive therapy [Online ahead of print]","author":"Mihara M","year":"2019","unstructured":"Mihara M, Ogawa Y, Nagasaka M, et al.. Successful management of acquired factor v inhibitor by monitoring factor V activity, antigen, and inhibitor values during immunosuppressive therapy [Online ahead of print]. Acta Haematol. 2019, 10.1159\/000502730","journal-title":"Acta Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7754\/clin.lab.2019.190240","article-title":"Acquired factor V deficiency associated with CFPM administration","volume":"65","author":"Yamanishi M","year":"2019","unstructured":"Yamanishi M, Nishimi Y, Usui M, Miki K, Imashuku S. Acquired factor V deficiency associated with CFPM administration. Clin Lab. 2019, 65:190240. 10.7754\/clin.lab.2019.190240","journal-title":"Clin Lab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308600200","article-title":"unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor","volume":"279","author":"Gould WR","year":"2004","unstructured":"Gould WR, Silveira JR, Tracy PB. unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor. J Biol Chem. 2004, 279:2383-2393. 10.1074\/jbc.M308600200","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10420","article-title":"High\u2010dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors","volume":"190","author":"de Raucourt E","year":"2003","unstructured":"de Raucourt E, Barbier C, Sinda P, Dib M, Peltier J, Ternisien C. High\u2010dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol. 2003, 190:187-190. 10.1002\/ajh.10420","journal-title":"Am J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.169","article-title":"Antigenicity of putative phospholipid membrane-binding residues in factor VIII","volume":"97","author":"Barrow RT","year":"2001","unstructured":"Barrow RT, Healey JF, Jacquemin MG, Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood. 2001, 97:169-174. 10.1182\/blood.v97.1.169","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2015.10.018","article-title":"Molecular mechanisms of membrane targeting antibiotics","volume":"1858","author":"Epand RM","year":"2016","unstructured":"Epand RM, Walker C, Epand RF, Magarvey NA. Molecular mechanisms of membrane targeting antibiotics. Biochim Biophys Acta. 2016, 1858:980-987. 10.1016\/j.bbamem.2015.10.018","journal-title":"Biochim Biophys Acta"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/34494-acquired-factor-v-inhibitor-after-antibiotic-therapy-a-clinical-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:57Z","timestamp":1707506577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/34494-acquired-factor-v-inhibitor-after-antibiotic-therapy-a-clinical-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.9481","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}